Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

November 10, 2017: By Jon Swedien

EYLEARegeneron reported Nov. 8 that net sales of Eylea (aflibercept) in the US totaled $953 million in Q3-2017, a 12 percent increase over Q3-2016 revenues of $854 million.

Bayer commercializes Eylea outside the US. In Q3-2017, net sales of Eylea outside of the US were $564 million, compared with $471 million in the third quarter of 2016, a 20 percent increase, Regeneron said. In Q3-2017, Regeneron recognized $205 million from its share of net profit from Eylea sales outside the US, compared with $171 million in Q3-2016.

About 70 percent of Eylea sold in the US goes to treat wet age-related macular degeneration and about 25 percent goes to treat diabetic macular edema (DME), said Manisha Narasimhan, PhD, Regeneron’s head of investor relations. Narasimhan said DME represents a significant growth opportunity for Eylea because a large majority of patients are not currently using an anti-VEGF treatment.

Regeneron, based in Tarrytown, New York, posted $1.5 billion in revenues in Q3-2017, compared with $1.2 billion in Q3-2016, a 23 percent increase.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023